CN110049969A - 喹啉类化合物、其制备方法及其医药用途 - Google Patents

喹啉类化合物、其制备方法及其医药用途 Download PDF

Info

Publication number
CN110049969A
CN110049969A CN201880004762.5A CN201880004762A CN110049969A CN 110049969 A CN110049969 A CN 110049969A CN 201880004762 A CN201880004762 A CN 201880004762A CN 110049969 A CN110049969 A CN 110049969A
Authority
CN
China
Prior art keywords
alkyl
butyl
chloro
tert
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880004762.5A
Other languages
English (en)
Inventor
司聚同
姜美锋
李加艳
曾含
杨华斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ancureall Pharmaceutical Shanghai Co Ltd
Original Assignee
Ancureall Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ancureall Pharmaceutical Shanghai Co Ltd filed Critical Ancureall Pharmaceutical Shanghai Co Ltd
Publication of CN110049969A publication Critical patent/CN110049969A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

本发明涉及一种喹啉类化合物、其制备方法及其医药用途。具体而言，本发明涉及一种通式(I)所示的新的喹啉类化合物、其制备方法，以及其作为多种蛋白激酶抑制剂的用途，特别是在预防和/或治疗癌症中的用途，其中，通式(I)中各基团的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201880004762.5A 2017-02-07 2018-02-06 喹啉类化合物、其制备方法及其医药用途 Pending CN110049969A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100676925 2017-02-07
CN201710067692 2017-02-07
PCT/CN2018/075392 WO2018145621A1 (zh) 2017-02-07 2018-02-06 喹啉类化合物、其制备方法及其医药用途

Publications (1)

Publication Number Publication Date
CN110049969A true CN110049969A (zh) 2019-07-23

Family

ID=63107198

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004762.5A Pending CN110049969A (zh) 2017-02-07 2018-02-06 喹啉类化合物、其制备方法及其医药用途

Country Status (3)

Country Link
US (1) US10800741B2 (zh)
CN (1) CN110049969A (zh)
WO (1) WO2018145621A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112194623A (zh) * 2020-10-16 2021-01-08 四川伊诺达博医药科技有限公司 一种乐伐替尼衍生物关键中间体的合成方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211203A1 (es) * 2018-01-26 2021-07-05 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
EP3743417A1 (en) 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN111320580B (zh) * 2018-12-14 2022-12-20 江苏先声药业有限公司 一种仑伐替尼中间体的制备方法
CN111377864B (zh) * 2018-12-27 2022-03-18 江苏先声药业有限公司 一种仑伐替尼杂质及其制备方法和应用
CN109776432B (zh) * 2019-03-21 2020-07-24 广州六顺生物科技股份有限公司 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用
CN113480479B (zh) * 2021-08-12 2022-08-02 上海爱博医药科技有限公司 脲类多靶点酪氨酸激酶抑制剂及其医药应用
CN115322149A (zh) * 2022-08-22 2022-11-11 思科(深圳)药物研发有限公司 一种甲磺酸仑伐替尼杂质及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308310C (zh) * 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
WO2016161952A1 (zh) * 2015-04-07 2016-10-13 广东众生药业股份有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018028591A1 (zh) * 2016-08-09 2018-02-15 殷建明 一种喹啉衍生物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308310C (zh) * 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
WO2016161952A1 (zh) * 2015-04-07 2016-10-13 广东众生药业股份有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KLUETER等: ""Displacement Assay for the Detection of Stabilizers of Inactive Kinase Conformations"", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112194623A (zh) * 2020-10-16 2021-01-08 四川伊诺达博医药科技有限公司 一种乐伐替尼衍生物关键中间体的合成方法

Also Published As

Publication number Publication date
WO2018145621A1 (zh) 2018-08-16
US10800741B2 (en) 2020-10-13
US20190375714A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
CN110049969A (zh) 喹啉类化合物、其制备方法及其医药用途
US10350210B2 (en) EGFR and ALK dual inhibitor
CN108349981B (zh) 新型的吡唑并[3，4－d]嘧啶化合物或其盐
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
TWI304061B (en) Nitrogen-containing aromatic ring derivatives
CA2720552C (en) Acylthiourea compound or salt thereof, and use thereof
CN109328059A (zh) Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN109790166A (zh) 咪唑并吡啶化合物用于治疗癌症
CN105899490A (zh) 嘧啶fgfr4抑制剂
US20190010159A1 (en) Novel kinase inhibitor against wild-type and mutant egfr
US20150152088A1 (en) Alkynyl heteroaromatic compound and use thereof
WO2016192609A1 (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
WO2015188747A1 (zh) 作为egfr抑制剂的苯基取代的三嗪类化合物及其应用
CN105968115B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
KR20190022929A (ko) Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
US9388165B2 (en) Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
CN110563697A (zh) 2-吡啶甲酰胺类化合物的制备及应用
WO2018137639A1 (zh) 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
WO2010096395A1 (en) Amides as kinase inhibitors
CN109641908A (zh) 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN104169258A (zh) 用作激酶活性调节剂的新颖的杂环羧酰胺
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
KR20210061202A (ko) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
WO2023024545A1 (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
CN106866642B (zh) 含芳基酰腙结构的喹唑啉类化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004129

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190723